お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:開放隅角緑内障治療薬の世界市場:2019年~2023年
市場調査レポート
商品コード
886893

開放隅角緑内障治療薬の世界市場:2019年~2023年

Global Open-Angle Glaucoma Therapeutics market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 123 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
開放隅角緑内障治療薬の世界市場:2019年~2023年
出版日: 2019年07月03日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 123 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

開放隅角緑内障は、開放隅角の存在下で視神経の進行性萎縮を引き起こす眼の症状です。2018年には、プロスタグランジン類似体(PGA)セグメントが大きな市場シェアを獲得しており、この傾向は予測期間中も続くと予想されます。第一選択治療の選択や他の薬とのPGAの組み合わせの使用の増加などの要因は、市場ポジションを維持するためにPGAセグメントにおいて重要な役割を果たすでしょう。また、世界の開放隅角緑内障治療薬市場では、有望なパイプラインおよび最近の承認、ならびに併用薬に対する需要の増加などが成長を促進する要因になっています。併用薬は、最小限の有害作用で疾患と戦うための異なる標的または経路を目的としています。さらに、それらはまた、2つの化合物がそれらの個々の用量閾値未満で使用され得るので、耐容性も改善します。併用薬の需要はこうしたメリットにより増加し、予測期間中に4%以上のCAGRで市場成長を促進する見込みです。 しかしながら、緑内障手術の進歩の不確実性、局所薬物療法の低い患者遵守、および開放隅角緑内障の無症候性の性質などが、予測期間にわたる緑内障治療業界の成長を妨げる可能性があります。

当レポートでは、世界の開放隅角緑内障治療薬市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • PGA
  • 非PGA
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31646

About this market

Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. Technavio's open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.

Overview

Increasing demand for combination drugs

Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.

Strategic alliances

The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global open-angle glaucoma therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.

Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • PGAs - Market size and forecast 2018-2023
  • Non-PGAs - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: PGAs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: PGAs - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Non-PGAs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Non-PGAs - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Projections for glaucoma (2010, 2030, and 2050)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Population aged 65 years and above (% of total) in Asia 2017
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Some late-stage drugs in pipeline for open-angle glaucoma treatment
  • Exhibit 44: Some of the combination drugs
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Aerie Pharmaceuticals Inc. - Vendor overview
  • Exhibit 52: Aerie Pharmaceuticals Inc. - Business segments
  • Exhibit 53: Aerie Pharmaceuticals Inc. - Organizational developments
  • Exhibit 54: Aerie Pharmaceuticals Inc. - Key offerings
  • Exhibit 55: Aerie Pharmaceuticals Inc. - Key customers
  • Exhibit 56: Allergan Plc - Vendor overview
  • Exhibit 57: Allergan Plc - Business segments
  • Exhibit 58: Allergan Plc - Organizational developments
  • Exhibit 59: Allergan Plc - Geographic focus
  • Exhibit 60: Allergan Plc - Segment focus
  • Exhibit 61: Allergan Plc - Key offerings
  • Exhibit 62: Allergan Plc - Key customers
  • Exhibit 63: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 64: Bausch Health Companies Inc. - Product segments
  • Exhibit 65: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 66: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 67: Bausch Health Companies Inc. - Segment focus
  • Exhibit 68: Bausch Health Companies Inc. - Key offerings
  • Exhibit 69: Bausch Health Companies Inc. - Key customers
  • Exhibit 70: Novartis AG - Vendor overview
  • Exhibit 71: Novartis AG - Business segments
  • Exhibit 72: Novartis AG - Organizational developments
  • Exhibit 73: Novartis AG - Geographic focus
  • Exhibit 74: Novartis AG - Segment focus
  • Exhibit 75: Novartis AG - Key offerings
  • Exhibit 76: Novartis AG - Key customers
  • Exhibit 77: Pfizer Inc. - Vendor overview
  • Exhibit 78: Pfizer Inc. - Business segments
  • Exhibit 79: Pfizer Inc. - Organizational developments
  • Exhibit 80: Pfizer Inc. - Geographic focus
  • Exhibit 81: Pfizer Inc. - Segment focus
  • Exhibit 82: Pfizer Inc. - Key offerings
  • Exhibit 83: Pfizer Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.